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Abstract
Background: Identification of gene-phenotype relationships is a fundamental challenge in human health clinic.
Based on the observation that genes causing the same or similar phenotypes tend to correlate with each other in
the protein-protein interaction network, a lot of network-based approaches were proposed based on different
underlying models. A recent comparative study showed that diffusion-based methods achieve the state-of-the-art
predictive performance.
Results: In this paper, a new diffusion-based method was proposed to prioritize candidate disease genes. Diffusion
profile of a disease was defined as the stationary distribution of candidate genes given a random walk with restart
where similarities between phenotypes are incorporated. Then, candidate disease genes are prioritized by
comparing their diffusion profiles with that of the disease. Finally, the effectiveness of our method was
demonstrated through the leave-one-out cross-validation against control genes from artificial linkage intervals and
randomly chosen genes. Comparative study showed that our method achieves improved performance compared
to some classical diffusion-based methods. To further illustrate our method, we used our algorithm to predict new
causing genes of 16 multifactorial diseases including Prostate cancer and Alzheimer’s disease, and the top
predictions were in good consistent with literature reports.
Conclusions: Our study indicates that integration of multiple information sources, especially the phenotype
similarity profile data, and introduction of global similarity measure between disease and gene diffusion profiles are
helpful for prioritizing candidate disease genes.
Availability: Programs and data are available upon request.
Background
Elucidating the relationship between human genetic dis-
eases and their causal genes is an important emerging
topic in current systematic biology. Understanding the
inherited basis of these interactions could both improve
medical care and better understand gene functions, inter-
actions, and pathways. Typically, a disease is associated
with a linkage interval of 0.5-10 cM on the chromosome if
single nucleotide polymorphisms (SNPs) in this interval
are correlated with an increased probability to have the
disease [1-3]. Then, these linkage intervals define a set of
(up to several hundreds) candidate disease-causing genes
[4,5].
With the rapid accumulation of different kinds of geno-
mic data, a lot of computational methods for prioritizing
candidate casual genes of a given phenotype were pro-
posed at the beginning of the 21st century. These methods
are largely based on the similarity of characteristics of dis-
ease genes, including sequence-based features [6-8],
expression patterns [9-11], and functional annotation data
[12,13]. Despite their good performances, these methods
suffer from some inherent limitations, e.g., the incomplete
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and false-positive disease-causal genes data, ambiguous
boundary between different diseases, and highly heteroge-
neous of diseases.
Recently, network-based analysis showed that gene
products related to the same disease are prone to physi-
cally interact with each other [14-17]. Based on this
observation, a number of computational approaches have
been proposed to predict associations between genes and
diseases. These methods mainly begin with an artificial
disease interval and test their ability to identify a real
causing gene among a fixed number of nearby control
genes. According to their underlying methodology, these
methods can be loosely grouped into three categories
[18]. The first category is the linkage methods, which
assumed that the direct interaction partners of a disease
protein are likely to associate with the same disease phe-
notype. It was found that gene products interacted with a
known disease protein were shown to be tenfold enriched
in true disease-causing genes [19], so many researchers
searched the PPI network for direct or indirect interact-
ing partners of known disease genes to find new possible
causing genes [10,20,21]. The second category is module-
based methods, which are based the observation that
gene products belonging to the same topological, func-
tional or disease module have a high likelihood of being
involved in the same disease. These methods inspect dis-
ease modules by graph partition algorithms and treat
their members as potential disease genes [22]. The last
category consists of diffusion-based methods [23-26]. In
these algorithms, ‘random walkers’ are released from the
protein products of known disease genes, and then dif-
fuse along the PPI network, with a certain probability to
return the original nodes. Compared to linkage-based
and module-based methods, diffusion-based methods
used information encoded in the full network topology as
well as the placement of all known disease genes. So a
recent comparative research found that diffusion-based
methods achieved the best predictive performance on the
same data set [27].
In the present paper, we propose a new diffusion-based
method to prioritize candidate disease genes. The diffusion
profile of a disease was defined as the stationary distribu-
tion of all candidate genes in the PPI network under a
random walk with restart where similarities between phe-
notypes are incorporated. Similarly, the diffusion profile of
a gene was obtained by smoothing the probability distribu-
tion over the whole network when starting a walk from
this gene. Then, candidate disease genes are prioritized by
comparing their diffusion profiles with that of the disease,
measured by the linear correlation coefficient and cosine of
the angle between profile vectors. Finally, the effectiveness
of our method was demonstrated through the leave-one-
out cross-validation against control genes from artificial
linkage intervals and randomly chosen genes. Comparisons
of our method with two classical diffusion-based methods
showed that our method achieves improved performance.
To further illustrate our method, we also used our algo-
rithm to predict new causing genes of 16 multifactorial dis-
eases including prostate cancer and Alzheimer’s disease,
and our top predictions are in good consistent with litera-
ture reports.
Methods
Protein-protein interaction data and known disease-gene
associations
The protein-protein interaction network (PPI) is mod-
elled as an undirected graph with nodes representing the
genes and edges representing the physical or binding
interactions between proteins encoded by the genes. In
the present paper, PPI network is obtained from release 9
of the Human Protein Reference Database (HPRD) [28].
After removing duplications and self-linked interactions,
we obtain 37 064 manually curated interactions between
9515 human genes.
Disease-gene association data are downloaded from the
Online Mendelian Inheritance in Man (OMIM) knowl-
edgebase [29]. The dataset contains 2704 diseases and
5316 disease-gene associations after removing the duplica-
tions, with an average of 1.97 gene associations for each
disease. To facilitate the cross-validation, diseases cur-
rently associated with only one causal gene were dis-
carded. Meanwhile, associations not correlated with the
9515 human genes in the PPI network were also excluded.
After these steps, a total number of 1238 validate disease-
gene associations left for further consideration.
Phenotype similarities between 5080 disease phenotypes
obtained from the literature [30] are incorporated for
prioritization of candidate disease genes. These similarities
are calculated by text mining of OMIM phenotype records
using Medical Subject Headings (MeSH) terms [31].
According to their analysis, similarity values below the
threshold 0.3 are not informative, while for similarity
values beyond 0.6 the associated genes show significant
functional similarity. So in our analysis, similarity values
below 0.3 are not considered for the computation of the
diffusion profile of a disease (Figure 1).
Random walk with restart and diffusion profile of a
protein
Given a PPI network G =< V,E > where V is the set of
proteins, E is the set of interactions. The random walk on
PPI network is defined as an iterative walker’s transition
from its current node to any neighbouring node with
equal probability starting at a given source node(s). In a
statistical point of view, a random walk is a finite Markov
chain that is time-reversible.
For example, if a random walk begins with a node
g ∈ V , the initial distribution P0 of the random walk was
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formulated as a vector of dimension ||V||, in which the
element in position corresponding to v was 1 and 0
otherwise. The rule of the walk can be expressed by the
equation
Pt+1 = M · Pt t = 0, 1, 2, · · · (1)
where M is the column-normalized adjacency matrix of
the graph. After a certain steps, the probability will reach a
steady (or stationary) state. This can be implemented by
performing the iteration until the difference between Pt+1
and Pt (measured by the L1 norm) fall below10 - 6, i.e.,
|Pt+1 − Pt| < 10−6 (2)
If the walk has a certain probability γ to return the start
node at each step, that is,
Pt+1 = (1 − γ )M · Pt + γP0 t = 0, 1, 2, · · · (3)
which is the random walk with restart. The restart prob-
ability γ enforces a restriction on how far we want the ran-
dom walker to get away from the start node v. If γ is close
to 1, the stationary probability vector reflects the local
structure around the v, and as γ gets close to 0, a more
global view is observed. Finally, we define the diffusion
profile of a protein g as the stationary distribution P∞ of
the random walk with the initial distributionP0.
Random walk with restart (RWR) provides a good rele-
vance between two nodes in a graph, and it has been suc-
cessfully used in numerous settings, like automatic
captioning of images, generalizations to the “connection
subgraphs”, personalized PageRank, and so on [32]. The
main advantage of the random walk method is that its
computational complexity is relatively low and applicable
to handle large PPI networks. Moreover, the method can
be used to compute the proximity of a node to a set of
source nodes (not just a single source node). This property
is especially beneficial when a core set of members of a
phenotype is known and the network is queried for candi-
date members.
Diffusion profile of a disease by incorporating OMIM
Phenotype similarity and prioritizing function
Similarly, in order to compute the diffusion profile of a
disease, we should first get the initial distribution of a dis-
ease. Here, the initial probability vector D0 of a disease d
was constructed such that equal probability was assigned
to each node representing the causing gene of the disease,
with the sum of the probabilities equals 1. Then
Dt+1 = (1 − γ )M ·Dt + γD0 t = 0, 1, 2, · · · (4)
In this way, proteins that interact with several disease
proteins will gain a high probabilistic weight, as well as
those that may not directly interact with any disease pro-
teins but are in close network proximity to them.
It was found by researchers that similar phenotypes are
caused by functionally related genes. Based on this obser-
vation, for a disease d, we used initial distributions of
Figure 1 Workflow of the DP_LCC method. i) The phenome-interactome network is constructed by integrating the PPI network, disease-gene
associations and currently known phenotype similarity data. ii) Diffusion profiles of diseases and genes are calculated by a random walk over the
PPI network with restart where similarities between phenotypes are incorporated. iii) Candidate genes are then prioritized according to their
similarities with the disease diffusion profile. The numbers on the edges of phenome network indicate their pairwise similarities.
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phenotypes which have similarity exceeds a threshold with
d to optimize its initial distribution. We assume that the
contribution of a given disease di is proportional to the
initial distribution of d. So the weighted initial distribution
of the disease d is formulated as
D˜0 = D0 + λ ·
5080∑
i=1
δ(d, di) · Sim(d, di) ·Di0 (5)
where δ(d, di) =
{
1 Sim(d, di) ≥ 0.3
0 otherwise
, Di0 is the initial dis-
tribution of disease di.
Then
D˜t+1 = (1 − γ )M · D˜t + γ D˜0 t = 0, 1, 2, · · · (6)
We called the stationary distribution D˜∞ of the ran-
dom walk diffusion profile of the disease d.
Finally, for a given disease and a set of genes in the
PPI network, the prioritizing function can be defined by
the Linear Correlation Coefficient (LCC, Figure 1) or
Cosine angle of their corresponding diffusion profiles.
Explicitly,
DLCC(d, g) = LCC(D˜∞,P∞) =
n∑
i=1



















If a gene has very similar stationary distribution profile
with a disease, it may have strong evidence to be the caus-
ing gene of the disease. Following this observation, given a
disease d, its candidate genes were ranked according to
the LCC and COS values between their stationary distri-
butions. We referred the two proposed candidate gene
prioritization algorithms as DP_LCC and DP_COS respec-
tively, where ‘DP’ is the abbreviation of ‘diffusion profile’.
Cross-validation and evaluation criteria
We used two leave-one-out cross-validation methods to
validate our algorithm. First is the artificial linkage interval
approach, which assumes the singled out interaction is
unknown and prioritizes the gene against a set of control
genes in the genome. Here the control set consists of the
nearest 99 genes around real disease causing genes accord-
ing to the UCSC refGene table. Actually, there may be few
undiscovered disease causing genes in the control set. Sec-
ond, we used validation against random genes, i.e., in each
run, a known disease-gene association is singled out as the
test sample against a set of 99 control genes that are
selected at random from all genes in the interactome. So,
a total of 100 genes (including the real disease-causing
gene) are served as test data, and performance of our
method is validated by capability to recover the real caus-
ing gene from the rest 99 control genes.
We used two measures to evaluate the performance of
the proposed method. For each cross-validation run, we
calculated the proportion of disease genes that obtain the
top prioritization score against the corresponding 99 con-
trol genes, and called this measure precision (PRE). Also,
given a threshold of rank ratio, we calculated the sensitiv-
ity (also called the true positive rate) as the fraction of dis-
ease genes ranked above this threshold and the specificity
(also called the true negative rate) as the fraction of con-
trol genes ranked below the threshold. Varying the thresh-
old of rank ratio from 0 to 1 with the scale 0.01, we are
able to draw a receiver operating characteristic (ROC)
curve and further calculate the area under this curve
(AUC). Clearly, a larger PRE/AUC values indicate a better
prediction performance of a prioritization method.
Results and discussion
Effects of parameters
There are two free parameters in our model, the restart
probability γ in the random walk algorithm and the weight
parameter λ in computing the initial probability of a dis-
ease. We tested our algorithm on different values of γ
(from 0 to 1 with the step 0.05) and λ (from 0 to 1 with
the step 0.1) and found that the best performance are got
at the weight parameterλ = 0.5, while the restart para-
meter γ only has slight effect on the results (Table 1). In
detail, for both DP_LCC and DP_COS, the highest PREs
are got at γ = 0.25 and λ = 0.5, and the largest AUC for
DP_LCC is got at γ = 0.7 and λ = 0.5, while for DP_COS
the values are γ = 0.5 and λ = 0.5, respectively. But in
general, PREs and AUCs did not change significantly at
different values of γ, which is in accordance with the
observation of Kohler, et al. (2008).
Table 1 Prediction accuracies of DP_LCC and DP_COS
at γ = 0.25
γ DP_LCC DP_COS
PRE AUC PRE AUC
0.1 406 0.7591 406 0.7590
0.2 412 0.7616 414 0.7606
0.3 417 0.7625 421 0.7624
0.4 422 0.7638 422 0.7625
0.5 422 0.7634 423 0.7618
0.6 421 0.7627 421 0.7612
0.7 419 0.7619 417 0.7609
0.8 419 0.7620 418 0.7605
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We tested our algorithm (DP_LCC) by two leave-one-
out cross-validation methods, i.e., artificial linkage inter-
val approach (ALI) and random genes approach (Rand).
Results are shown in Figure 2 and suggest a similar per-
formance of DP_LCC by ALI and Rand validations. The
only slight difference lies at low values of false positive
rates between 0 and 0.1, with a slight superiority of
Rand. But when false positive rate increases from 0.1 to
1, two ROC curves are nearly coincident, with AUCs
0.7710 (Rand) and 0.7634 (ALI) respectively. The similar
performance of our algorithm by two cross-validation
approaches demonstrates that: (i) the control genes by
random chosen and from artificial linkage interval are
unbiased; (ii) our algorithm is robust to the selection of
control set.
The parameter λ controls the contribution of other
related phenotypes to the initial distribution of a pheno-
type. Large λ introduce more global dependence of rank-
ing between different correlated phenotypes. When λ = 0,
the proposed method could be very similar to the RWR
algorithm. To investigate the effect of this parameter, we
set various values of λ ranging from 0.1 to 0.9, the perfor-
mance of our algorithm measured by two evaluation cri-
teria are shown in Table 1. The performances of our
algorithm evaluated by two criteria, i.e., LCC and COS,
have no significant difference at different values of λ. The
performance is improved when λ ranges from 0.1 to 0.5,
and decreased when λ is larger than 0.6, especially at 1.0.
Therefore, we suggest the λ value of 0.4 or 0.5.
Comparison with other diffusion-based methods
To illustrate the utility of the present method, we com-
pared the performances of DP_LCC and DP_COS with
two diffusion-based methods, i.e, the RWR and PRINCE
on the same gene-phenotype network. Both methods
used random walk with restart algorithm to prioritize dis-
ease-candidate genes, and achieved relatively better per-
formance compared to linkage-based methods and graph
partitioning-based methods [27]. The only difference
between RWR and PRINCE is the construction of initial
distribution of a disease, where the initial probability vec-
tor of RWR was constructed such that equal probability
was assigned to each causing gene of a disease, and in
PRINCE, the prior information vector was initialized by
incorporating disease similarity information by using a
logistic function. In our implement, two free parameters
c and d in logistic function are set to -15 and log(9999)
respectively, which are in accordance with PRINCE.
We use leave-one-out cross-validation to evaluate the
performance of different diffusion-based methods in
recovering the gene-phenotype relationship. In each
round, a gene-phenotype link was removed, and the rest
Figure 2 ROC curves of DP_LCC by different leave-one-out cross-validation methods. ALI: artificial linkage interval approach; Rand: random
genes approach.
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causal genes and associating phenotypes were used as
training set to recover this link. We evaluated the per-
formance of an algorithm in terms of precision (PRE)
and the area under ROC curve (AUC) at different values
of the rank ratio. The results are shown in Table 2 and
Figure 2. As is shown, the proposed method is superior
to RWR and PRINCE at nearly all parameter settings in
terms of both PRE and AUC. For all these three algo-
rithms, the highest precisions, i.e, 384, 459 and 423 for
RWR, PRINCE and our method, respectively, are
obtained at γ = 0.25. At parameter set λ = 0.5, our
methods (DP_LCC and DP_COS) successfully ranked
422 and 423 known disease genes as top 1 out of the
total 1238 disease-gene interactions. In contrast, only
384 and 359 disease genes were ranked at the top by
RWR and PRINCE. While for AUC, the tendency was a
little different. AUCs of the RWR algorithm drops with
the increase of γ, and the highest value 0.7549 was
achieved at γ = 0.1. Similar phenomenon was observed
for PRINCE. It is worth mentioning that this phenom-
enon is slightly different from the result of Kohler [23],
who found that the best performance was achieved at
γ = 0.75. However, the PRINCE algorithm, which also
took into consideration the phenotype similarity data,
did not achieve high predictive accuracies especially
when γ is larger. This phenomenon may be attributed
to the setting of parameters c and d, which are tuned
using cross validation over a totally different dataset, are
not quite suitable for the current dataset. We believed
that after a careful optimization of the parameters, the
PRINCE would achieve a better accuracy than RWR due
to the incorporation of phenotype similarities.
The ROC curves for these three methods at γ = 0.7
are shown in Figure 3. We used the receiver operating
characteristic (ROC) curve to compare our method with
two diffusion-based methods, which plots the sensitivity
versus 1-specificity subject to the threshold separating
the prediction classes [9]. Sensitivity refers to the per-
centage of disease genes that were ranked above a parti-
cular threshold. Specificity refers to the percentage of
non-disease genes ranked below this threshold. As
shown in Figure 3, the curve of our algorithm is above
those of RWR and PRINCE, which suggest that our
algorithm obtained both higher sensitivity and higher
specificity. The AUC value of our algorithm is 0.7698,
which is much higher than RWR (0.7465) and PRINCE
(0.6017).
Another popular method for evaluating the perfor-
mance of a prioritization method is to consider the pre-
cision-recall curve [24,33,34]. Given the association
scores calculated for candidate genes, we define positive
calls as all genes whose association scores are higher
than a certain threshold and define the precision as the
proportion of disease genes among the positive calls.
And the recall, also called the true positive rate, is
defined as the proportion of positively called disease
genes among all disease genes. By varying the threshold
value, we can compute a series of precision and recall
values and obtain a precision-recall (PR) curve. The PR-
curves for RWR, PRINCE and our method are shown as
Figure 4. As is shown, the curve of our method also lies
above those of RWR and PRINCE, which suggests that
the performance of our method is superior to the other
diffusion-based methods. The superior performance of
our model may be attributed to the incorporation of
OMIM Phenotype similarities, as well as the global simi-
larity measures between diffusion profiles of diseases
and candidate causing genes.
Predict novel causing genes of Prostate cancer and
Alzheimer’s disease
After validating our method, we proceeded to execute
our algorithm to predict new causing genes of 16 multi-
factorial diseases that are linked to multiple genomic
regions (Table 3). According to the MIM record, all
these 16 diseases are associated with more than 10
known valid causing genes locating at different genomic
regions. We used our algorithm to predict new causing
genes for these 16 diseases, where known causing genes
are served as training data and the rest genes in the PPI
Table 2 Performances of different algorithms at different values of γ
Method 0.1 0.2 0.25 0.3 0.4 0.5 0.6 0.7 0.8 0.9
RWR PRE 370 379 384 380 380 377 371 370 370 369
AUC 0.7549 0.7549 0.7542 0.7527 0.7507 0.7493 0.7477 0.7465 0.7451 0.7435
PRINCE PRE 350 352 359 351 341 329 309 287 263 229
AUC 0.7457 0.7372 0.7309 0.7235 0.7027 0.6758 0.6427 0.6017 0.5429 0.4371
The present worka PRE_LCC 405 417 422 419 419 417 415 414 413 407
AUC_LCC 0.7487 0.7616 0.7634 0.7643 0.7659 0.7674 0.7688 0.7698 0.7683 0.7694
PRE_COS 407 421 423 419 421 418 412 411 412 406
AUC_COS 0.7473 0.7604 0.7618 0.7631 0.7637 0.7644 0.7638 0.7636 0.7619 0.7606
a The pensions are divided by/1238; run time of our algorithm is 38 minutes. Computations were performed on a single processor of a dual-core Intel (R) Core
P8700 2.53 GHz and 2 GB GB of shared memory.
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Figure 3 Comparison of the proposed method with two diffusion-based methods.
Figure 4 Precision-recall curves of three diffusion-based methods.
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network are served as candidate disease genes. The top-
10 predictions for each disease are shown in Table 3.
We selected Alzheimer’s disease (MIM: 104300), Pros-
tate cancer (MIM: 176807), Diabetes Mellitus, type 2
(MIM: 125853) as three case studies.
Alzheimer’s disease (AD) is the most common cause of
dementia in the elderly. It is characterized clinically by
progressive memory loss that leads eventually to dementia.
As is shown in Table 3, the third prediction for AD is
TREM2 (Triggering Receptor Expressed on Myeloid cells),
which is a member of the innate immune receptor TREM
family [35,36]. It is expressed on the cell surface of the
monocyte-macrophage lineage including monocyte
derived dendritic cells, osteoclasts and microglia in the
Central Nervous System (CNS) [37,38]. Recent researches
showed that TREM2 deficiency originates a genetic syn-
drome characterized by bone cysts and presenile dementia
[39]. Another prediction, MAPT, was also a suspicious dri-
ver gene for AD [40-43]. Genetic variability at the MAPT
locus was shown to be associated with increased risk for
the sporadic tauopathies, PSP [44] and corticobasal degen-
eration [45]. The fifth prediction is PSEN1, which is also a
driver gene of AD in the literature. It was reported that
mutations in the human presenilin genes (PSEN1 and
PSEN2) are associated with early onset familial Alzheimer
disease [46].
Diabetes is a chronic condition associated with abnor-
mally high levels of sugar (glucose) in the blood. The dis-
ease can be classified into three different categories: the
type I, type II and the gestational diabetes. The top 3 pre-
dictions of our algorithm for Diabetes mellitus are
ABCG8, ABCG5 and PPP1R3A, respectively. The first two
genes, i.e., ABCG5 and ABCE8, are ATP-binding cassette
transporters that are located in a head-to-head orientation
on chromosome 2. The proteins are expressed in the liver,
intestine [47,48], and gallbladder epithelial cells [47]. Poly-
morphisms in ABCG5/ABCG8 genes might contribute to
the genetic variation in plasma lipid levels and in choles-
terol saturation of the bile [49]. Down-regulation of hepa-
tic and intestinal Abcg5 and Abcg8 expression associated
with altered sterol fluxes in rats with streptozotocin-
induced diabetes [50]. In addition, defects in Rp1 and
PPP1R3A are also causes of susceptibility to diabetes mel-
litus of type I and II, respectively [51].
Prostate cancer is the most common malignancy in men
and the second leading cause of male cancer-related
deaths in the Western world. According to the OMIM
record, prostate cancer has 25 validate causing genes.
Based on these 25 known genes and causing genes of tex-
tual related phenotypes, we predicted novel causing genes
of prostate cancer using our method (DP_LCC). As is
shown in Table 3, the top 3 predictions for prostate cancer
are TP53, RET and DHCR24, where TP53 is an important
suppressor involved in several types of cancer [52,53].
According to the IARC TP53 Mutation Database [54],
inactivating TP53 mutations are detected at frequencies in
the range of 10-20% in primary prostate cancer [55]. TP53
was also predicted as the tops by PRINCE. Our second
prediction for prostate cancer is RET, which was also
found to be overexpressed in high-grade (histopathologi-
cally advanced) prostatic intraepithelial neoplasia (PIN)
and prostate cancer [56]. So RET was supposed to play a
role in the growth of both benign and neoplastic prostate
epithelial cells. Another two predicted causing genes,
DHCR24 and STK11, were also consistent with the litera-
ture. Specifically, DHCR24 is one of androgen receptor-
regulated genes implicated in prostate carcinogenesis [57],
and STK11 was reported to be inactivated in prostate
Table 3 Top 10 predicted causal genes of 16 multifactoral diseases predicted by DP-LCC
Phenotype Name PhenoID Top-10 predictions for each phenotype by our algorithm
Alzheimer disease 104300 PAH TYROBP TREM2 MAPT PSEN1 SIGLEC14 CD300E NCR2 CLEC5A HLA-DQB1
Breast cancer 114480 PAH DHCR24 SMYD2 SHISA5 FBXO11 MTM1 TSC1 TSC2 MTMR12 STK11
Colon cancer 114500 MLH1 BRCA2 MSH2 PMS2 VHL DHCR24 SHISA5 SMYD2 FBXO11 EXO1
Diabetes mellitus 125853 ABCG8 ABCG5 PPP1R3A RP1 CFTR B2M F2 APC PLN CD1E
Gastric cancer 137215 MLH1 PTCH2 MSH2 PMS2 ESR1 SMO PTCH1 EXO1 PNLIP IHH
Atrial fibrillation 147050 RAG2 RAG1 CPN1 IGF1R KL IL2 IFNA1 CPN2 MEN1 PRSS1
Prostate cancer 176807 TP53 RET DHCR24 SMYD2 SHISA5 FBXO11 STK11 NTRK1 CDKN2A BCL7A
Schizophrenia 181500 PAH GLO1 TYROBP TREM2 MAPT MTM1 MTMR12 SIGLEC14 CD300E NCR2
Leukemia/lymphoma 190685 POMT1 POMT2 PAH TYROBP TREM2 CHRNA1 NSD1 CHRNE FGFR2 CHRND
Lung cancer 211980 TP53 CDKN2A SFTPA2 SFTPA1 ZFP91 ZNF227 TBRG1 KIAA1984 CDKN2AIP ANKRD12
Zellweger syndrome 214100 PEX19 ETFB ETFA PEX6 PEX1 PEX12 POMT2 POMT1 SLC25A17 PEX11A
Leukemia 253310 BSCL2 CHRNA1 CHRNG DOK7 C5orf62 TMEM19 USE1 CHRND RAPSN MUSK
Asthma 600807 MARCO SCGB3A1 RFXAP RFX5 HPS1 HPS4 RFXANK IL6 MPO IL2
Leukemia 601626 MPL THPO AMPD1 PDGFRB HES5 FANCE FANCD2 BRCA2 ATXN2L MYH2
Obesity 601665 MC3R ATRNL1 MC1R MC5R ASIP MC2R NPY NPY5R SIGLEC6 GHRHR
Tuberculosis 607948 NDUFV2 UMOD HSPA4 AGRP ASIP IFNGR2 HPN TUBA4A GGCX LTB
Zhu et al. BMC Bioinformatics 2013, 14(Suppl 5):S5
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cancer, through mutation analysis of 24 known cancer
genes in the NCI-60 cell line set [58].
Conclusion
In this paper, a diffusion-based method incorporating pair-
wise similarities of phenotypes was proposed to prioritize
candidate disease genes. The novelty of our method lies in
the incorporation of disease phenotypes (OMIM pheno-
type data) from the literature to the initial state of the
RWR, and the usage of global similarity between diffusion
profiles of disease and genes. Diffusion profiles of diseases
and genes are obtained by walking over the protein-pro-
tein interaction network under a given initial distribution,
where the initial distribution of a disease was weighted by
OMIM Phenotype similarities exceeding a threshold. Then
the linear correlation coefficient and cosine of the angle
between profiles of a disease and given genes were com-
puted to rank the priorities with the disease. Leave-one-
out cross-validation on a benchmark dataset showed that
our method achieved a higher precision (measured by PRE
and AUC) than existing diffusion-based methods. This
result suggests that the proposed algorithm effectively cap-
tures the interplay between gene network and phenotype
network. We finally predicted causing genes of 16 multi-
factorial diseases including Prostate cancer and Alzhei-
mer’s disease using our algorithm and found that parts of
our predictions are in good accordance with current
experimental reports.
The superior performance of our method was attribu-
ted to the following aspects. First, integration of multi-
ple information sources, especially the phenotype
similarity profile data. Second, global similarity measures
(linear correlation coefficient and cosine function of the
angle) between diffusion profiles of diseases and genes
are introduced to prioritize candidate disease genes. In
contrast to previous methods that prioritize candidate
disease genes through comparing their corresponding
components in the diffusion profile of a disease, our glo-
bal-based method could take into consideration the dis-
tribution values of other genes in the PPI network.
Consequently, in the future work, we can integrate
some other genomic information to further improve our
method, such as gene expression data, functional annota-
tions, pathway membership and so on. Moreover, many
researchers pointed out that some diseases might be
attributed to a certain protein complexes composed by
multiple proteins or a certain pathways. So furthermore
attention should be paid on elucidating associations
between diseases and protein complexes or pathways.
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